Komplex célszerv-védelem korszeru vérnyomáscsökkentokkel

Translated title of the contribution: Prevention of target organ damages with modern antihypertensive therapy

D. Páll, E. Katona, Mária Juhász, G. Paragh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This review summarises the recent epidemiological data on hypertension, the aims of the treatment of hypertension, and emphasizes the importance of the modification of target organ damages and accelerated clinical conditions. Because the pathogenesis of hypertension is extremely complex, the therapy most likely requires a combined drug administration. The modern third generation dihydropirydin calcium channel blocker, amlodipine, not only has a favourable antihypertensive and antiischaemic effect, but antiatherosclerotic properties as well. There are plenty of evidence which demonstrate that lisinopril, a first line antihypertensive agent, has a positive effect in the treatment of left ventricular hypertrophy, retinopathy and nephropathy, and also has a favourable outcome after myocardial infarction and in heart failure. The combined administration of the two drugs leads to a favourable additive effect, with a decrease in the number and severity of side effects. The results of the ASCOT study proved a favourable effect with amlodipine based, combination therapy with an ACE-inhibitor, compared with the traditional beta-blockers and diuretics. The data of the CAFÉ sub-study showed, that in spite of the similar peripheral antihypertensive effect, the amlodipine based therapy decreased the central aortic pulse pressure to a greater extent. The central aortic pressure showed a good correlation with the end-points of the study, respectively. The results of the Hungarian multicentre study (HAMLET) proved the effective and safety administration of the two drugs in combination. Based on the above mentioned evidences, the fixed-dose combination of the CCB-ACE inhibitor (amlodipine - lisinopril) has not only an effective blood pressure decreasing properties, but also results in cardiovascular risk reduction, good tolerability and favourable compliance.

Original languageHungarian
Pages (from-to)1505-1511
Number of pages7
JournalOrvosi Hetilap
Volume147
Issue number32
Publication statusPublished - Aug 13 2006

Fingerprint

Amlodipine
Antihypertensive Agents
Lisinopril
Hypertension
Angiotensin-Converting Enzyme Inhibitors
Arterial Pressure
Calcium Channel Blockers
Left Ventricular Hypertrophy
Drug Combinations
Risk Reduction Behavior
Therapeutics
Diuretics
Pharmaceutical Preparations
Compliance
Multicenter Studies
Heart Failure
Myocardial Infarction
Blood Pressure
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Komplex célszerv-védelem korszeru vérnyomáscsökkentokkel. / Páll, D.; Katona, E.; Juhász, Mária; Paragh, G.

In: Orvosi Hetilap, Vol. 147, No. 32, 13.08.2006, p. 1505-1511.

Research output: Contribution to journalArticle

@article{63de14f9992f4a58b67c83b4c347b0b4,
title = "Komplex c{\'e}lszerv-v{\'e}delem korszeru v{\'e}rnyom{\'a}scs{\"o}kkentokkel",
abstract = "This review summarises the recent epidemiological data on hypertension, the aims of the treatment of hypertension, and emphasizes the importance of the modification of target organ damages and accelerated clinical conditions. Because the pathogenesis of hypertension is extremely complex, the therapy most likely requires a combined drug administration. The modern third generation dihydropirydin calcium channel blocker, amlodipine, not only has a favourable antihypertensive and antiischaemic effect, but antiatherosclerotic properties as well. There are plenty of evidence which demonstrate that lisinopril, a first line antihypertensive agent, has a positive effect in the treatment of left ventricular hypertrophy, retinopathy and nephropathy, and also has a favourable outcome after myocardial infarction and in heart failure. The combined administration of the two drugs leads to a favourable additive effect, with a decrease in the number and severity of side effects. The results of the ASCOT study proved a favourable effect with amlodipine based, combination therapy with an ACE-inhibitor, compared with the traditional beta-blockers and diuretics. The data of the CAF{\'E} sub-study showed, that in spite of the similar peripheral antihypertensive effect, the amlodipine based therapy decreased the central aortic pulse pressure to a greater extent. The central aortic pressure showed a good correlation with the end-points of the study, respectively. The results of the Hungarian multicentre study (HAMLET) proved the effective and safety administration of the two drugs in combination. Based on the above mentioned evidences, the fixed-dose combination of the CCB-ACE inhibitor (amlodipine - lisinopril) has not only an effective blood pressure decreasing properties, but also results in cardiovascular risk reduction, good tolerability and favourable compliance.",
keywords = "Amlodipine, Fixed-dose combination, Hypertension, Lisinopril, Target organ damage",
author = "D. P{\'a}ll and E. Katona and M{\'a}ria Juh{\'a}sz and G. Paragh",
year = "2006",
month = "8",
day = "13",
language = "Hungarian",
volume = "147",
pages = "1505--1511",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "32",

}

TY - JOUR

T1 - Komplex célszerv-védelem korszeru vérnyomáscsökkentokkel

AU - Páll, D.

AU - Katona, E.

AU - Juhász, Mária

AU - Paragh, G.

PY - 2006/8/13

Y1 - 2006/8/13

N2 - This review summarises the recent epidemiological data on hypertension, the aims of the treatment of hypertension, and emphasizes the importance of the modification of target organ damages and accelerated clinical conditions. Because the pathogenesis of hypertension is extremely complex, the therapy most likely requires a combined drug administration. The modern third generation dihydropirydin calcium channel blocker, amlodipine, not only has a favourable antihypertensive and antiischaemic effect, but antiatherosclerotic properties as well. There are plenty of evidence which demonstrate that lisinopril, a first line antihypertensive agent, has a positive effect in the treatment of left ventricular hypertrophy, retinopathy and nephropathy, and also has a favourable outcome after myocardial infarction and in heart failure. The combined administration of the two drugs leads to a favourable additive effect, with a decrease in the number and severity of side effects. The results of the ASCOT study proved a favourable effect with amlodipine based, combination therapy with an ACE-inhibitor, compared with the traditional beta-blockers and diuretics. The data of the CAFÉ sub-study showed, that in spite of the similar peripheral antihypertensive effect, the amlodipine based therapy decreased the central aortic pulse pressure to a greater extent. The central aortic pressure showed a good correlation with the end-points of the study, respectively. The results of the Hungarian multicentre study (HAMLET) proved the effective and safety administration of the two drugs in combination. Based on the above mentioned evidences, the fixed-dose combination of the CCB-ACE inhibitor (amlodipine - lisinopril) has not only an effective blood pressure decreasing properties, but also results in cardiovascular risk reduction, good tolerability and favourable compliance.

AB - This review summarises the recent epidemiological data on hypertension, the aims of the treatment of hypertension, and emphasizes the importance of the modification of target organ damages and accelerated clinical conditions. Because the pathogenesis of hypertension is extremely complex, the therapy most likely requires a combined drug administration. The modern third generation dihydropirydin calcium channel blocker, amlodipine, not only has a favourable antihypertensive and antiischaemic effect, but antiatherosclerotic properties as well. There are plenty of evidence which demonstrate that lisinopril, a first line antihypertensive agent, has a positive effect in the treatment of left ventricular hypertrophy, retinopathy and nephropathy, and also has a favourable outcome after myocardial infarction and in heart failure. The combined administration of the two drugs leads to a favourable additive effect, with a decrease in the number and severity of side effects. The results of the ASCOT study proved a favourable effect with amlodipine based, combination therapy with an ACE-inhibitor, compared with the traditional beta-blockers and diuretics. The data of the CAFÉ sub-study showed, that in spite of the similar peripheral antihypertensive effect, the amlodipine based therapy decreased the central aortic pulse pressure to a greater extent. The central aortic pressure showed a good correlation with the end-points of the study, respectively. The results of the Hungarian multicentre study (HAMLET) proved the effective and safety administration of the two drugs in combination. Based on the above mentioned evidences, the fixed-dose combination of the CCB-ACE inhibitor (amlodipine - lisinopril) has not only an effective blood pressure decreasing properties, but also results in cardiovascular risk reduction, good tolerability and favourable compliance.

KW - Amlodipine

KW - Fixed-dose combination

KW - Hypertension

KW - Lisinopril

KW - Target organ damage

UR - http://www.scopus.com/inward/record.url?scp=33750113677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750113677&partnerID=8YFLogxK

M3 - Article

C2 - 16981424

AN - SCOPUS:33750113677

VL - 147

SP - 1505

EP - 1511

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 32

ER -